A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients

Conditions: Diabetic Macular Edema Interventions: Genetic: SKG0106 intravitreal injection dose level 1, 2 or 3 Sponsors: Wang Min; Lanyue Biotech (Hangzhou) Co., Ltd. Recruiting

https://clinicaltrials.gov/study/NCT06237777

Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials